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Abstract
 
Much remains to be learned about the physiologic events that promote monocytes to become
lymph-homing dendritic cells (DCs). In a model of transendothelial trafficking, some monocytes
become DCs in response to endogenous signals. These DCs migrate across endothelium in the
ablumenal-to-lumenal direction (reverse transmigration), reminiscent of the migration into
lymphatic vessels. Here we show that the subpopulation of monocytes that expresses CD16
(Fc
 
 
 
 receptor III) is predisposed to become migratory DCs. The vast majority of cells derived
from CD16
 
 
 
 monocytes reverse transmigrated, and their presence was associated with migratory
cells expressing high levels of CD86 and human histocompatibility leukocyte antigen (HLA)-DR,
and robust capacity to induce allogeneic T cell proliferation. A minority of CD16
 
 
 
 monocytes
reverse transmigrated, and these cells stimulated T cell proliferation less efficiently. CD16 was
not functionally required for reverse transmigration, but promoted cell survival when yeast
particles (zymosan) were present as a maturation stimulus in the subendothelial matrix. The cell
surface phenotype and migratory characteristics of CD16
 
 
 
 monocytes were inducible in
CD16
 
 
 
 monocytes by preincubation with TGF
 
 
 
1. We propose that CD16
 
 
 
 monocytes may
contribute significantly to precursors for DCs that transiently survey tissues and migrate to
lymph nodes via afferent lymphatic vessels.
Key words: antigen presentation • cell survival • transforming growth factors • IgG receptors • 
cell differentiation
 
Introduction
 
Antigen-presenting dendritic cells (DCs)
 
*
 
 initiate immune
responses after they capture antigen from peripheral tissues
and then migrate to lymph nodes where they efficiently
interact with T cells to drive T cell activation and prolifer-
ation. Circulating HLA-DR
 
 
 
 human DC precursors include
CD14
 
 
 
CD64
 
 
 
CD11c
 
 
 
 cells (1, 2), the IFN-
 
 
 
–producing
CD123
 
 
 
CD11c
 
 
 
 plasmacytoid cells (3), and CD14
 
 
 
CD64
 
 
 
CD11c
 
 
 
 monocytes (4). The former cell types are
committed DC precursors, but monocytes differentiate into
macrophages unless redirected to a DC phenotype by cyto-
kines. Empirical approaches have defined several cytokine
cocktails that promote differentiation of DCs from monocytes
(5–8). However, whether these cytokines or other signals
account for how monocytes differentiate into DCs in a
tissue environment is unknown.
To study how monocytes become DCs in a tissue setting,
we employed a previously characterized model in which
some monocytes differentiate into DCs in response to cues
that are endogenous to an endothelial cell/collagen culture
(4). In this model, monocytes first migrate across an endo-
thelial monolayer to enter a subendothelial collagen matrix.
Those monocytes that will become DCs retraverse the intact
endothelium in the ablumenal-to-lumenal direction (reverse
transmigration; references 4 and 9), a step that shares common
features with the trafficking of DCs from tissues into the
lumen of lymphatic vessels. These shared features include a
key role for the ABC lipid transporter MDR-1 (ABCB1)
in mediating both reverse transmigration in this model and
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the mobilization of skin DCs through authentic dermal
lymphatic vessels (10, 11).
When phagocytic particulates like zymosan are incorpo-
rated in the underlying collagenous matrix, reverse-trans-
migrated cells acquire phenotypic and functional features of
mature, terminally differentiated DCs (4). In the absence of
an exogenous stimulus or inclusion of phagocytic particles
in the subendothelial matrix, the reverse-transmigrated cells
do not possess features of fully mature DCs, but bear char-
acteristics more consistent with immature DCs (4). Instead
of developing into DCs, monocyte-derived cells that do
not reverse transmigrate but remain in the subendothelial
collagen differentiate into macrophages (4).
In this study, we pursued whether differentiation of
monocytes into reverse-transmigratory DCs or more sessile
macrophages is stochastic or whether a population of
monocytes is predisposed to become DCs in conjunction
with their migration across endothelium. Our findings sup-
port the latter possibility. Here we show that the distinct
CD16
 
 
 
 subset of blood monocytes (12) have the greatest
propensity among monocytes to develop into migratory
DCs. CD16 participates in the survival of these cells in re-
sponse to zymosan activation and can be induced by
TGF
 
 
 
1. TGF
 
 
 
1 not only induces expression of CD16, as
shown previously (13), but we find that it yields cells with
an overall surface phenotype of CD16
 
 
 
 blood monocytes,
enhances migration, and promotes survival. In contrast to
TGF
 
 
 
1, other cytokines, including IL-10 and M-CSF, that
have been reported to induce CD16 expression in mono-
cytes did not recapitulate the phenotype of circulating
CD16
 
 
 
 monocytes. Overall, these data indicate that
CD16
 
 
 
 monocytes have the greatest capacity among
monocytes to become trafficking DCs and highlights the
possibility that this subset develops in response to TGF
 
 
 
1.
 
Materials and Methods
 
Flow Cytometry.
 
Antibodies used for flow cytometric staining
included purified mAbs to CD3, CD14, CD19, CD36, CD64,
CD86, HLA-DR, HLA-DP (all from BD Biosciences), E-cad-
herin (Santa Cruz Biotechnology, Inc.), and IgM nonbinding
control (BD Biosciences), CD83 (Serotec), control mAb UPC10
(Sigma-Aldrich), and CD16 (Mederex; and additional mAb given
by Dr. Jay Unkeless, Mt. Sinai School of Medicine). Cell surface
staining was detected with FITC-conjugated rabbit anti–mouse Ig
(Dako). Multi-color analysis was conducted using PE-conjugates
of anti-HLA-DR or anti-CD14 mAbs, FITC-conjugated CD64,
and biotin-conjugates of anti-CD16 or anti-CD86 mAbs (BD
Biosciences), followed by detection with streptavidin allophyco-
cyanin (APC; Caltag).
 
Leukocyte Isolation.
 
Blood from healthy donors was drawn ac-
cording to guidelines approved by the Internal Review Board of
Mt. Sinai School of Medicine. PBMCs were isolated by density
gradient centrifugation on Ficoll. Magnetic depletion of NK cells
or CD16
 
 
 
 populations were performed using anti-CD56 and
anti-CD16 miniMACS (Miltenyi Biotec). Depletion of
M-DC8
 
 
 
 cells was conducted by incubating PBMCs with di-
luted M-DC8 hybridoma supernatant, followed by incubation
with FITC-conjugated anti–mouse Ig and removal by flow cyto-
metric cell sorting. The M-DC8 mAb was the gift of Dr. E. Peter
Rieber, Institute for Immunology in Dresden, Germany. For car-
boxyfluorescein diacetate succinimidyl ester (CFSE) labeling,
CD16
 
 
 
 cells were isolated by flow cytometric cell sorting using
3G8 anti-CD16 mAb followed by detection with FITC-conju-
gated rabbit anti–mouse Ig. For allogeneic T cell proliferation
studies, cell sorting was conducted by first depleting B and T cells
from the PBMC population with anti-CD3, anti-CD19, and
CD56 miniMACS, and then staining with PE-conjugated CD14.
Cells with high forward scatter were separated according to level
of expression of CD14, and CD14
 
 
 
 cells were discarded.
 
Reverse Transmigration Assay.
 
Reverse-transmigrated and sub-
endothelial leukocytes were studied using previously described
methods (4). In brief, second passage human umbilical vein endo-
thelial cells (HUVEC) were cultured on bovine type I collagen
gels (Cohesion) in microtiter wells and used for experiments ap-
proximately three days after reaching confluence. Zymosan parti-
cles (0.0002%; wt/vol) were included during the polymerization
of some collagen gels. For experiments, whole PBMCs were ap-
plied to the endothelium, incubated for 1.5 h, washed thor-
oughly in medium to remove nonmigrated cells from above the
endothelium, and continued in culture for 48 h. Culture medium
consisted of 20% heat-inactivated human serum in Medium 199
(M199). After 48 h, reverse-transmigrated cells were collected
from above the endothelium by gentle pipetting in the presence
of 1 mM EGTA. Subendothelial cells were analyzed after diges-
tion of the collagen with Collagenase D (Boehringer) for 40 min.
In some experiments, anti–MDR-1 mAb MRK16 (gift of Dr.
Isamu Sugawara, Research Institute for Tuberculosis, Tokyo, Japan),
isotype-matched control IgG UPC10 (Sigma-Aldrich), or anti-
CD16 mAb 3G8 was added to the cultures at 2–10 
 
 
 
g/ml after the
initial 1.5 h incubation in which monocytes migrated into the sub-
endothelial collagen as described previously (10). Antibodies added
to the cultures have the capacity to cross the endothelium and gain
access to subendothelial monocytes within 5 h of incubation.
Whole PBMCs or CD16
 
 
 
 PBMCs isolated by flow cytometry
were labeled with 2 
 
 
 
M CFSE (Molecular Probes) for 15 min at
37
 
 
 
C in protein-free Hank’s buffered saline. Then these cells
were remixed with CD16
 
 
 
 monocytes and added to endothelial
cultures for assessment of reverse transmigration.
 
Mixed Leukocyte Reaction.
 
Allogeneic T cells were purified
from PBMCs by depletion with anti-HLA II magnetic beads
(Dynal). Live reverse-transmigrated cells to be evaluated as candi-
date APCs were irradiated with 3,000 rad, and triplicate cultures
containing 1.25 
 
 
 
 10
 
3
 
 reverse-transmigrated cells were cultured
with 10
 
5
 
 T cells per well. After 5 d of culture, 1 
 
 
 
Ci of [
 
3
 
H]thy-
midine was added per well for an additional 15 h.
 
Cytokine Treatments.
 
PBMCs were cultured under nonadher-
ent conditions in Teflon beakers containing 10 ng/ml recombi-
nant human TGF
 
 
 
1, 20 ng/ml recombinant human IL-10, 10–
50 ng/ml recombinant M-CSF, or rabbit pan anti–human TGF
 
 
 
neutralizing antibody (10 
 
 
 
g/ml, added daily) in M199 contain-
ing 10% heat-inactivated human serum. All of these reagents
were purchased from R&D Systems. After culture, cells were
washed and prepared for reverse transmigration experiments,
conducted as with freshly isolated PBMCs.
 
Results
 
CD16 Expression on Subpopulations of HLA-DR
 
 
 
 Mono-
cytes and DC Precursors.
 
The HLA-DR
 
 
 
 fraction of PBMCs
that lack characteristics of B lymphocytes represent 
 
 
 
20% 
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of PBMCs and contain several subpopulations that col-
lectively comprise potential precursors for antigen-pre-
senting DCs. These HLA-DR
 
 
 
 cells can be subdivided
into several distinct populations, as shown in Fig. 1:
CD14
 
 
 
 nonmonocytic DCs that contain a very small frac-
tion of CD123
 
 
 
 plasmacytoid cells, and CD14
 
 
 
 monocytes
that can be divided into CD16
 
 
 
 and CD16
 
 
 
 fractions. The
CD14
 
 
 
CD16
 
 
 
 monocytes can be further subdivided into
cells that do or do not express the DC subset marker
M-DC8 (14, 15). The CD16
 
 
 
 subpopulation of mono-
cytes expresses only an intermediate level of CD14 relative
to CD16
 
 
 
 monocytes (12; Fig. 1). These cells exhibit re-
duced levels of other markers associated with macrophage
activities, including CD36 and the high affinity Fc
 
 
 
 recep-
tor CD64 (Fig. 1). In contrast, CD16
 
 
 
 monocytes exhibit
somewhat elevated levels of accessory molecules, including
CD86, HLA-DR (16), and HLA-DP (Fig. 1). These data
indicate that CD16
 
 
 
 monocytes more closely resemble
DCs than do CD16
 
 
 
 monocytes.
 
CD16
 
 
 
 Monocytes Traverse Endothelial Monolayers.
 
When
the whole PBMC fraction is applied to the apical surface
of cultured endothelial monolayers not pretreated with
proinflammatory cytokines, very few B or T lymphocytes
migrate beneath the endothelium, but a majority of mono-
cytes (17, 18) and NK cells (19) will undergo trans-
endothelial migration in less than 2 h of incubation. This
step mimics the trafficking of these cells from the vascular
compartment into subendothelial connective tissue, and in
the absence of exogenous cytokine stimulation, may reflect
populations of leukocytes that leave the blood in the
steady-state. We conducted experiments to evaluate whether
the CD16
 
 
 
 monocytes were among those that efficiently
traversed the endothelium. We also examined the transmi-
gration of the previously defined CD14
 
 
 
CD64
 
 
 
HLA-DR
 
 
 
nonmonocytic DCs (1, 2), as their interaction with endo-
thelium directly after isolation has not been reported. Flow
cytometric cell sorting of this fraction of HLA-DR
 
 
 
CD14
 
 
 
 cells confirmed the differentiation of these cells
into mature DCs after cultured in macrophage conditioned
medium (unpublished data) as reported previously (1), in-
dicating that the CD14 cells we tracked were indeed DC
precursors. Both CD16
 
 
 
 and CD16
 
 
 
 monocytes migrated
efficiently across unstimulated endothelium (Fig. 2), with
more than two-thirds of each population entering the
subendothelial collagen. On a relative basis, CD16
 
 
 
 mono-
cytes migrated somewhat more efficiently than CD16
 
 
 
monocytes. Among the CD16
 
 
 
 cells that entered the col-
lagen gel, 15 to 25% were M-DC8
 
 
 
 (unpublished data).
Similar extents of transendothelial migration occurred in
endothelial cultures in which zymosan, a preparation of
yeast cell membranes, was embedded in the type I collagen
matrix (unpublished data). In contrast, less than half of
CD14
 
 
 
CD64
 
 
 
CD11c
 
 
 
HLA-DR
 
 
 
 DC precursors traversed
the endothelium (Fig. 2).
 
CD16
 
 
 
 Monocytes Preferentially Reverse Transmigrate.
 
Next we followed the expression of CD16 by monocyte-
derived cells present in endothelial/collagen cultures for
48 h, during which time nearly half of the originally trans-
migrated cells retraverse the endothelium in the ablumenal-
to-lumenal direction (reverse transmigration). In endothe-
lial cultures receiving no exogenous stimulus such that the
reverse-transmigrated population fails to differentiate into
Figure 1. Cell surface markers distinguish CD16  and CD16 HLA-
DR  PBMCs. Freshly isolated PBMCs were depleted of CD56  NK
cells. Two-color flow cytometry was conducted with a gate set to ex-
clude smaller PBMCs of the lymphocyte lineage. Expression of macro-
phage-associated markers CD14, CD36, and CD64 or DC-associated
markers HLA-DR, HLA-DP, and CD86 (all x-axis) were examined.
Cells were counterstained with a mAb to CD16 (y-axis). Some cells were
stained with M-DC8 mAb to identify a subset of CD16  cells (reference
11). Quadrant markers (shown in CD14 and CD123 panels) are posi-
tioned according to the level of fluorescence observed in cells stained
with nonbinding isotype-matched control mAbs (lower left quadrant,
negative staining). The phenotype illustrated was similarly observed
among four donors examined.
Figure 2. Transendothelial
migration of blood DC precur-
sors across unstimulated endo-
thelium. The entire fraction of
freshly isolated PBMCs were in-
cubated with endothelial cell/
collagen cultures for 1.5 h to
permit transmigration. The api-
cal surface of the cultures was
washed to collect nonmigrated
cells, and the migrated popula-
tion was recovered from the sub-
endothelial collagen using colla-
genase D. Cells considered for
quantitative evaluation were
large mononuclear cells (LMC)
uniformly positive for HLA-DR
and negative for the B cell marker CD19 or T cell marker CD3. The plot
shows the percent distribution of three distinct populations:
CD14 CD16 , CD14 CD16 , and CD14 CD16  cells. The total
height of each bar represents the relative distribution of these populations
in freshly isolated PBMCs. The filled portion of each bar indicates the
fraction of each population that emigrated beneath the endothelium, and
the open portion of each bar represents the portion of the population that
was recovered in the nonmigrated fraction. These data are representative
of results obtained using PBMCs from three different blood donors. 
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fully mature DCs, most or all of the reverse-transmigrated
cells expressed CD16 (Fig. 3 A), and as many as 20% of
these cells were M-DC8
 
 
 
 (unpublished data). However,
the cell surface density of CD16 declined by about half
during the 1.5 h incubation when monocytes entered the
subendothelial collagen (unpublished data), relative to the
level expressed in blood. This reduced level of CD16 was
maintained throughout the culture period (Fig. 3, compare
level of CD16 in blood monocyte to that expressed by re-
verse-transmigrated cells). Overt activation of the cultures
with proinflammatory cytokines (unpublished data) or in-
clusion of zymosan in the collagen promoted complete loss
of CD16 in the reverse-transmigrated population (Fig. 3
B), consistent with its documented downregulation during
maturation of DCs.
In contrast to the reverse-transmigrated cells recovered
from unstimulated cultures, the vast majority of monocyte-
derived cells remaining in the subendothelium were
CD16
 
 
 
 (Fig. 3) and M-DC8
 
 
 
 (unpublished data). That
CD16
 
 
 
 cells could be recovered from the subendothelial
collagen after only 1.5 h of incubation (Fig. 2) argues that
our failure to detect CD16 on the surface of monocyte-
derived cells that remained in the subendothelium was not
due to cleavage of the relevant CD16 epitope during re-
covery of these cells from the collagen using collagenase D.
Furthermore, CD16
 
 
 
 cells were recovered from the suben-
dothelial matrix after 48 h when we prevented reverse
transmigration using an antagonist to the p-glycoprotein
lipid transporter ABCB1 (10; Fig. 4).
We conducted cell tracking experiments to evaluate
whether cells in the reverse-transmigrated population in-
deed arose from circulating CD16
 
 
 
 monocytes. Labeling
monocytes with CFSE at 2 
 
 
 
M did not alter the migratory
patterns of monocyte-derived cells within the cultures (Fig.
3 C). To focus on the migratory behavior of CD16
 
 
 
monocytes, these cells were isolated by flow cytometric cell
sorting, labeled with CFSE and then mixed with unlabeled
CD16
 
  PBMCs to match their original frequency in the
population (15% of total monocytes). We then traced the
distribution of CFSE-containing cells in the reverse-trans-
migrated and subendothelial monocyte-derived fractions
after 48 h of culture with endothelial cell/collagen matri-
ces. CFSE  cells comprised approximately half of the re-
verse-transmigrated population, which represents a great
enrichment of these cells in the migratory fraction (Fig. 3),
relative to their frequency in the overall population. In to-
tal, 85% of all CFSE CD16  cells were in the reverse
transmigrated fraction, whereas only 34% of CD16  cells
reverse transmigrated. Given the strong association of
CD16 expression with reverse transmigration, we assessed
whether CD16 was functionally required for reverse trans-
migration. Inclusion of the neutralizing anti-CD16 mAb
3G8 in these cultures (no zymosan) did not block reverse
transmigration.
Figure 3. Distribution of CD16  monocyte-derived cells after cocul-
ture with endothelial cells grown on collagen. (A) Expression of CD16
was monitored in monocyte/endothelial cocultures at 48 h, when the
majority of cells that will reverse transmigrate have done so. Assessments
were made in reverse transmigrated (R/T, thin-lined profile) and suben-
dothelial (S/E, bolded line profile) monocyte-derived cells from cultures
that received no activation stimuli such as exogenous cytokines or phago-
cytic particles. Dotted line demarcates the staining intensity of cells incu-
bated with isotype-matched mAbs to an irrelevant antigen. Filled profile
represents the expression of CD16 in freshly isolated monocytes. (B) In
other cultures, zymosan was included in the collagen to promote DC
maturation. In some unstimulated endothelial cultures, the whole fraction
of PBMCs (C) or CD16  monocytes sorted using flow cytometry (D),
were labeled with CFSE. Transendothelial migration into the collagen
and subsequent reverse transmigration was evaluated to assess the distribu-
tion of CFSE  cells. CFSE-labeled CD16  monocytes were remixed
with CD16  PBMCs so that CD16  CFSE  cells represented 15% of the
total population (D).
Figure 4. Effect of a reverse transmigration antagonist on the distribu-
tion of CD16  cells in endothelial cell cultures. PBMCs were incubated
with endothelial/collagen cultures for 1.5 h, then washed to remove non-
adherent, nonmigrated cells. Cultures were fed with medium containing
mAb to MDR-1 or isotype-matched control mAb UPC10, and incuba-
tion was continued for 48 h to allow reverse transmigration. The presence
of CD16  cells in reverse-transmigrated and subendothelial leukocytes
was monitored after 48 h by flow cytometry. The total number of
CD16  cells recovered from cultures in the presence and absence of anti-
MDR-1 is shown. The fraction of such cells that had reverse transmi-
grated (R/T) is shown by the open portion of the bars, whereas the frac-
tion that remained in the subendothelium (S/E) is shown by the filled
portion of the bars.521 Randolph et al.
Expression of CD16 Promotes Survival after Activation by
Zymosan. Next we compared the effects on the yield of
DCs recovered from endothelial cultures that received PB-
MCs that included or lacked CD16  monocytes. CD56 
NK cells, which also express CD16 and can migrate be-
neath the endothelium (19), were always first depleted
from the PBMC preparation before addition of mononu-
clear cells to the endothelium. When these cells remained
present, they had a deleterious effect on the viability of ac-
tivated DCs in the presence of zymosan, consistent with
the recently described role of NK cells in killing immature
DCs (20). After depletion of CD56  cells, the remaining
CD16  PBMCs were CD16 CD14  monocytes and these
were present together with CD16  monocytes in control
cultures (referred to as CD16mix monocytes). For compari-
son, the total fraction of CD16  cells were removed by
magnetic depletion, leaving only CD16  monocytes. The
depletions of the desired population were greater than 95%.
Although the above studies failed to show a functional
role for CD16 in migration, we observed that zymosan
stimulation after magnetic depletion of CD16  monocytes
led to a decreased viability in the reverse-transmigrated
population (Fig. 5 A). However, viability was uniformly
high in the absence of this maturation stimulus. To deter-
mine whether survival was functionally related to expres-
sion of CD16, we conducted experiments in which
CD16mix monocytes were added to endothelial cultures
with or without inclusion of zymosan in the collagen ma-
trix. In some wells, monocytes were treated with neutraliz-
ing anti-CD16 mAb. In zymosan-containing cultures, the
yield of live reverse-transmigrated DCs was reduced by
75% in the presence of anti-CD16 mAb (Fig. 5 B). These
data suggest that stimulation of monocytes with this micro-
bial particulate leads to cell death in the absence of func-
tional CD16. Anti- CD16 mAb did not prevent phagocytic
uptake of zymosan (unpublished data).
Differentiation and Migration Analysis after Depletion of
CD16  Monocytes. In some depletion experiments, only
the M-DC8  subpopulation of CD14 CD16  monocytes
was removed. Removal of M-DC8  cells only had no
marked effect on the yield or phenotype of reverse-trans-
migrated cells (unpublished data), but when the depletion
scheme eliminated all CD16  monocytes (CD16 depleted),
47   22% (P   0.05; four experiments) to 66   13% (P  
0.005; four experiments) fewer reverse transmigrated cells
were recovered from unstimulated and zymosan-stimulated
cultures, respectively (Fig. 6 A). These results are in agree-
ment with the CFSE experiments in Fig. 3. Even after
thorough depletion of CD16  monocytes, many reverse-
transmigrated cells recovered from cultures receiving only
the CD16  monocytes expressed CD16 upon reverse
transmigration, in contrast to the subendothelial monocyte-
derived cells from the same cultures (Fig. 6 B). Thus, these
cells appear to upregulate CD16 expression during reverse
transmigration. When flow cytometry was conducted to
analyze the maturation status of cells in the reverse-trans-
migrated fraction, the number of HLA-DR CD86  cells
was 63   14% (average of three experiments; P   0.005)
decreased per unit area of endothelial cell surface when
blood CD16  monocytes were depleted from the starting
population (Fig. 6 C; cells shown in each group were re-
covered from an equivalent area of endothelial surface).
Moreover, the residual DCs recovered after depletion of
CD16  monocytes expressed an order of magnitude less
CD86 on the cell surface, indicating that these reverse-
transmigrated, CD16  monocyte-derived cells were less
mature than the reverse-transmigrated cells that develop in
cultures that contained CD16  blood monocytes.
Role of Monocyte Subsets in Giving Rise to Antigen-present-
ing Cells that Stimulate Proliferation of Allogeneic T Cells.
The negative effects of anti-CD16 mAb on cell survival
obviated experiments in which we sorted CD16  mono-
cytes using anti-CD16 mAb and then added them to endo-
thelial cultures to assess differentiation and antigen-present-
ing capacity after encounter with a potent maturation
Figure 5. Viability of reverse-transmigrated cells in the presence or ab-
sence of functional CD16. The viability of reverse-transmigrated cells was
assessed by trypan blue staining after recovery from cultures lacking or
containing zymosan. (A) Viability assessment from cultures in which
CD16-depleted monocytes (CD16 ) or the full fraction of monocytes
containing both CD16  and CD16  subpopulations (CD16mix) were ap-
plied to the endothelium. (B) Recovery of live CD16mix monocytes in
the presence of neutralizing anti-CD16 mAb 3G8 was calculated in rela-
tion to the number of live cells recovered in the presence of isotype-
matched control antibody UPC10 under each condition.522 CD16 Identifies Migratory Monocyte-derived DCs
stimulus such as subendothelial zymosan. Instead, we ap-
proached comparing the antigen-presenting cell function of
these subsets after reverse transmigration using cell isolation
techniques that did not leave residual anti-CD16 mAb on
CD16  cells. We reasoned that if CD16  monocytes con-
tributed significantly to the majority of mature antigen-
presenting, reverse-transmigrated cells that their absence
would result in reduced T cell proliferative responses.
However, it was also important to be sure that any T cell
proliferation observed did not arise from stimulation by the
relatively rare CD14 CD11c  DCs (1, 2). Thus, we sepa-
rated monocyte subsets based on their level of CD14 stain-
ing (CD14  cells were discarded), as most CD16  mono-
cytes express lower levels of CD14 (CD14med) than CD16 
monocytes (CD14hi). As there is some breadth in the spec-
trum of CD14 that is expressed by CD16  monocytes, this
approach did not achieve absolute purity of the two sub-
sets, but did result in populations that were greatly enriched
for one or the other subset (Fig. 7). Some of the sorted
CD14hi cells were finally depleted completely of CD16 
monocytes using anti-CD16 magnetic beads. All popula-
tions were then applied separately to endothelial monolay-
ers containing zymosan in the subendothelial matrix. The
presence of CD16  monocytes in the population applied
was correlated with recovery of reverse-transmigrated cells
that exhibited robust capacity to induce T cell proliferation
(Fig. 7). Mixing reverse-transmigrated cells from CD16-
depleted cultures with reverse-transmigrated cells derived
from a population highly enriched in CD16  monocytes
led to an overall inhibitory effect, consistent with the
possibility that reverse-transmigrated cells derived from
CD16  monocytes differentiated into presentation-suppres-
sive macrophages (21) in the absence of CD16  monocytes
(Fig. 7). The presence of relatively few CD16  monocytes
amongst total monocytes added to endothelial cultures
curbed this inhibitory effect (Fig. 7, compare d and b to d
and c), raising the possibility that CD16  cells may not
only become DCs themselves but that they may also pro-
mote differentiation of reverse-transmigrated cells derived
from CD16  monocytes toward a DC-like phenotype
(Figs. 6 and 7).
Treatment with TGF 1 Induces CD16  Monocytes to Ac-
quire Similar Properties of Circulating CD16  Monocytes.
The origin of CD16  monocytes and their relationship to
CD16  monocytes are unknown. TGF 1, IL-10, and
M-CSF have been previously shown to induce expression of
CD16 on monocytes (13, 22–24), and neutralizing endoge-
nous TGF  with anti-TGF  antibody prevents “spontane-
ous” up-regulation of CD16 by cultured monocytes (13).
However, whether this cytokine induced other characteristic
features of CD16  monocytes was not studied. We depleted
PBMCs of CD16  cells and then cultured the remaining
CD16  monocytes under nonadherent conditions in TGF 1
or neutralizing anti-TGF  antibody (to prevent spontaneous
induction) for up to 3 d. Within an overnight period of cul-
ture, TGF 1 treatment induced CD16 (Fig. 8 A), as ex-
pected from previous reports (13). During this time period,
some other features of blood CD16  monocytes (as shown in
Fig. 1) became apparent, such as the slightly higher expression
of CD86 and increased HLA-DP that typify CD16  mono-
cytes (Fig. 8A, compare with Fig. 1). Other markers that dis-
tinguish CD16  monocytes from their CD16- counterparts
took longer to become apparent. After 3 d of culture in
TGF 1, levels of CD14 were reduced by one-half to one
log, just as observed on circulating CD16  monocytes.
Moreover, the slight increase in HLA-DR and somewhat de-
creased levels of CD64 that are observed in CD16  blood
monocytes were also acquired during culture with TGF 1.
Figure 6. Evaluation of reverse transmigration
and expression of CD16 after depletion of periph-
eral blood CD16  monocytes. CD56  NK cells
were depleted from the starting PBMC fraction,
leaving a fraction of PBMCs that included both
CD16  and CD16 (CD16mix) CD14  monocytes.
In some samples, the remaining CD16  cells were
depleted, leaving CD56 CD16  PBMCs. CD16mix
or CD16  PBMCs were applied to endothelial/
collagen cultures at the same starting density. The
number of reverse transmigrated cells in the
CD16  fraction was evaluated after 2 d and com-
pared in five independent experiments to the num-
ber of reverse transmigrated cells in the control
CD16mix population of PBMCs (A). The relative
recovery was calculated by setting equal to 1.0 the
number of reverse transmigrated cells recovered per
well of cultured endothelium after application of
CD56 CD16mix PBMCs and then determining the
fractional recovery in each experiment when
CD16-depleted PBMCs were applied. (B) The
possibility that CD16 might be upregulated on peripheral blood cells that originally lacked CD16 was tested by examining the expression of CD16 in re-
verse-transmigrated and subendothelial populations after full depletion of CD16  blood cells. Flow cytometric evaluation of CD16 expression in reverse
transmigrated (R/T) and subendothelial (S/E) cells that arose from CD16-depleted PBMCs is plotted as a histogram. (C) Phenotyping for CD86 and
HLA-DR expression was conducted in reverse-transmigrated populations derived in the presence or absence of CD16  monocytes. The dot plots shown
in panel C represent the number and phenotype of cells recovered from equal numbers of zymosan-containing endothelial cell microtiter cultures to
which equivalent densities of CD16mix and CD16  monocytes were applied.523 Randolph et al.
Although occasionally observed, the M-DC8 antigen was
not consistently up-regulated in response to TGF 1. The
Langerhans cell marker E-cadherin was not expressed on
these TGF 1-treated monocytes (unpublished data), even
though TGF 1 is known to induce E-cadherin on mono-
cytes that are additionally cocultured in GM-CSF and IL-4.
In contrast to our results with TGF 1, culturing CD16 
monocytes with IL-10 was accompanied by down-regulation
of HLA-DR and CD86, and culturing in M-CSF failed to
induce CD16 within the 3 d period tested (unpublished data).
When TGF 1 and anti-TGF  treated cultured mono-
cytes were applied to unstimulated endothelial monolayers,
the TGF 1-treated cells were much more migratory and
nearly twice as many entered the subendothelial collagen
(Fig. 8 B). The extent of reverse transmigration was also
greater in the TGF 1-treated cells, even when we corrected
for the different levels at which the two populations initially
crossed the endothelium (Fig. 8 C). These data suggest that
TGF 1 can regulate potential for reverse transmigration.
We also added TGF 1 and anti-TGF  treated mono-
cytes to zymosan-containing cultures. In contrast to
TGF 1-treated cells, the majority of reverse-transmigrated
cells from anti-TGF -treated cultures died rapidly after re-
verse transmigration, as the viability of these cells was low
(Fig. 8 D). This finding is in agreement with the previous
experiments in which expression of CD16 promoted sur-
vival of maturing DCs after phagocytic uptake of zymosan
(Fig. 6). Overall, culture of CD16  monocytes with
TGF 1 invokes expression of a number of phenotypic and
functional features that mimic CD16  blood monocytes,
consistent with the possibility that TGF 1 participates in
the development of this subset in vivo.
Discussion
A subpopulation of CD14  monocytes that expresses the
Fc  receptor CD16 (Fc RIII) has been previously defined
(12). This population represents  15% of circulating
monocytes in a normal individual. The origin, biologic ac-
tivity, and fate of CD16  monocytes has been enigmatic.
Although early reports concerning the functional capacity
of CD16  monocytes suggested that these cells had low ca-
pacity to stimulate autologous T cell proliferation (25), a
recent study concluded that CD16  monocytes possess the
highest capacity among freshly isolated blood leukocytes,
including CD14  DC precursors, to promote allogeneic T
cell proliferation (16). Here we provide evidence that this
subpopulation of monocytes is predisposed to become mi-
gratory DCs, and they may also impact development of an
antigen-presenting cell phenotype in CD16  monocyte-
derived cells. Depletion of CD16  monocytes or monitor-
ing their migration after CFSE labeling indicates that blood
CD16  monocytes are much more likely to join the re-
verse-transmigrating DC population than monocytes de-
rived from the CD16  fraction. Furthermore, as DCs de-
rived from CD16  monocytes show increased potential for
survival after phagocytic stimulation, DCs derived from
these precursors become even more enriched in the migra-
tory fraction when phagocytic antigens are present in the
subendothelial matrix.
It is unlikely that expression of CD16 by monocyte-
derived cells is invariably associated with development of
DCs. Whereas our data argue that CD16 expression by hu-
man monocytes is associated with an increased potential to
become DCs and that induction of CD16 expression by
TGF 1 induces a similar phenotype, the expression of
CD16 may also occur under other circumstances in re-
sponse to stimuli that are not otherwise associated with de-
velopment of migratory DCs. The expression of CD16 by
tissue macrophages (26) has led to the idea CD16  mono-
cytes bear a close relationship with tissue macrophages. In
contrast to our observations herein, the kinetics of CD16
upregulation by monocytes that become tissue macro-
phages is quite delayed and does not occur until after about
6 d in culture (27). At this stage, the developing macro-
phage may have diminished capacity to differentiate into a
DC. Indeed, there appears to be heterogeneity of CD16 
Figure 7. Capacity of reverse-transmigrated cells derived from mono-
cyte subsets to stimulate allogeneic T cell proliferation. Monocytes were
sorted according to their level of expression of CD14. First lymphocytes
were removed from the PBMC fraction to generate a “presort” popula-
tion of monocytes (a). Monocytes were then sorted into CD14hi (b, c)
and CD14med (d) expressing cells. Some of the CD14hi monocytes were
then treated with anti-CD16 miniMACs beads to remove any remaining
CD16  cells (c). These populations were added to endothelial cultures in
which zymosan was present in the subendothelial matrix, and then live
reverse transmigrated cells collected 2 d later were tested for their ability
to induce allogeneic T cell proliferation at a ratio of 1 antigen-presenting
cell: 80 T cells. In some conditions, a 1:1 mix of some reverse-transmi-
grated populations (d   b, or d   c) were used as APCs. Background
counts for T cells cultured alone were  300. This pattern of responses
was observed in 2 independent analyses.524 CD16 Identifies Migratory Monocyte-derived DCs
cells found within tissues in vivo, with some positive cells
illustrating typical features of macrophages lacking expres-
sion of HLA-DR, and others coexpressing HLA-DR (26).
It is important to note that although CD16 expression ap-
pears to signify potential to become migratory DCs, we
observe that CD16 is rapidly lost upon stimulation. Thus,
CD16  monocytes with the capacity to become migratory
DCs may not be readily detected in situ due to the tran-
sient nature of its expression.
Besides TGF 1, IL-10 has been reported to rapidly up-
regulate CD16 expression on monocytes (22). However,
we found that, in contrast to TGF 1, IL-10 promoted the
downregulation of CD86 and HLA-DR. Thus, stimulation
by IL-10 may lead to the differentiation of CD16  mac-
rophages, rather than DCs. It is also possible that IL-10 may
promote the development of a CD16  DC precursor in
particular cytokine environments that we did not study.
Ancuta and colleagues induced CD16 expression on mono-
cyte-derived cells by culturing them in the simultaneous
presence of three cytokines: IL-10, GM-CSF, and IL-4
(28). These cells developed key features of typical DCs
(28), although their migratory properties were not studied.
It will be important to determine whether this combination
of cytokines fully recapitulates the onset of the CD16 
monocyte phenotype. Although we know little about the
expression of combinations of particular cytokines in vivo,
it may be more likely that a single cytokine, endogenous
TGF 1, mediates the differentiation of CD16  monocytes
in vivo. The kinetics of induction of CD16  monocyte-
like cells from CD16  monocytes in vitro is also consistent
with the circulating half-life of human monocytes in vivo
(29). However, the in vivo environment in which mono-
Figure 8. Effect of TGF 1 on the phenotype, migratory
ability, and survival of CD16  monocytes. PBMCs were
depleted of CD16  cells using miniMACS magnetic selec-
tion. Then remaining cells were cultured for up to 3 d in
TGF 1 (bold lines) or anti-TGF  (thin lines) to block ac-
tivity of endogenous TGF . (A) The cell surface pheno-
type of these cultured cells was assessed by flow cytometry.
Control mAb staining is depicted as a dashed line in top
left histogram. (B) Monocytes cultured overnight in
TGF 1 or anti-TGF  were applied to endothelial mono-
layers grown on collagen gels lacking zymosan and apical-
to-basal transendothelial migration was quantified after a
1.5 incubation. (C) Reverse transmigration was quantified
at 48 h as the percent of cells that originally migrated across
the endothelium in each condition and then later retra-
versed the endothelium in ablumenal-to-lumenal direc-
tion. (D) Percentage of live cells in the reverse transmi-
grated populations derived from TGF 1 or anti-TGF 
treated monocytes incubated with endothelial cultures
lacking or containing zymosan within the subendothelium
was assessed by trypan blue exclusion.525 Randolph et al.
cytes would encounter TGF 1 is uncertain; it is possible
that this differentiation occurs in the bone marrow before
release of monocytes into the circulation.
Understanding the biological role of the CD16  subset of
monocytes may shed light on the mechanisms of disease and
host responses in some clinical settings, because the fre-
quency of CD16  monocytes in the blood varies dramati-
cally in association with disease states, inflammatory condi-
tions, and during immune-modulating therapy (30). For
example, clinical administration of GM-CSF (23) or gluco-
corticoids (31) reduces the number of circulating CD16 
monocytes to nearly undetectable levels, whereas M-CSF
treatment augments their frequency to as high as 80% of total
monocytes (23, 24). The effect of M-CSF is likely indirect,
as the kinetics of CD16 upregulation in response to this cy-
tokine are quite delayed, and we were unable to observe on-
set of the CD16  monocyte phenotype during 3 d of culture
with this cytokine. The fraction of monocytes that express
CD16  is also increased, for example, in patients burdened
with metastatic carcinoma (24), and in persons infected with
HIV (32, 33). Patients suffering from AIDS-related dementia
manifest a particularly dramatic increase in CD16  mono-
cytes, and these cells may have a key role in the neurodegen-
erative pathology (33, 34). It is of interest to determine
whether the increased levels of CD16  monocytes that are
observed during inflammatory diseases may be related to an
increased production of TGF 1.
One of the distinctive features of CD16  monocytes is
their superior capacity to produce TNF  (32). Inasmuch as
their trafficking capacity is consistent with the possibility
that CD14 CD16  monocytes give rise to DCs that may
survey tissues constitutively and thereby possibly participate
in peripheral tolerance, it is interesting to note that TNF 
stimulation of immature DCs renders a population that
promotes tolerance in vivo rather than immune priming
(35). The steady-state trafficking of self antigens, such as
melanin, to lymph nodes may be mediated by a TGF 1-
dependent antigen-presenting cell (36). TGF 1-dependent
DCs other than Langerhans cells (37) have not been re-
ported, but our data suggest that migratory monocyte-
derived DCs may depend upon TGF 1 as well. It was
concluded that the carriage of melanin to lymph nodes in
the steady-state was not mediated by monocyte-derived
cells (36), based on the prolonged in vivo use of a neutral-
izing anti–M-CSF antibody. However, considering that it
is likely that an immune response to the foreign antibody
developed and thereby attenuated its effectiveness after sev-
eral weeks of administration, this conclusion may require
reevaluation.
If monocytes give rise to a population of constitutively
trafficking DCs, a concept that is consistent with the condi-
tions and kinetics of their migration in vivo, they may con-
tribute significantly to peripheral tolerance. CD16  mono-
cytes have also been suggested to participate preferentially
in Th2 immunity. Sanchez-Torres and coworkers evaluated
the role of the two blood subsets, CD16  and CD16 
monocytes, by first separating them and then monitoring
their acquisition of DC features after incubation in IL-4/
GM-CSF and TNF- . Whereas both subsets exhibited the
capacity to differentiate into DCs in this model, T cells co-
cultured with DCs derived from CD16  monocytes se-
creted IL-4 upon stimulation, whereas DCs from CD16 
monocytes produced IL-12 and promoted Th1-like cyto-
kine production in T cells (38). DCs derived from CD16 
monocytes may have been biased toward Th2 responses
due to their purification using anti-CD16 mAb-coated
minibeads, as a recent report indicates that Th1 responses
can be converted to Th2 responses by targeting Fc  recep-
tors (39). However, the possibility that CD16  DC precur-
sors may participate in Th2 polarization is interesting con-
sidering that we have also uncovered a key role for CCR8
in mediating reverse transmigration (unpublished data), and
in vivo studies indicate that CCR8 /  mice manifest
greatly diminished Th2 responses without diminution of
Th1 immunity (40). Future studies to determine whether a
subpopulation of monocytes exists in mice that are analo-
gous to the CD16  blood monocyte population and the
role of CCR8 in their migration are needed.
The biologic function of CD16 expressed by monocytes
that later develop into migratory DCs appears to include
promoting survival in response to a phagocytic stimulus.
CD16 is specialized for recognition of immune complexes,
but it is also likely that CD16 is directly involved in bind-
ing to zymosan via serum amyloid proteins that opsonize
zymosan and are ligands for Fc receptors (FcRs; reference
41). Although other FcRs (41), integrins (42), and toll-like
receptors (43) are involved in the uptake and/or response
to zymosan in the absence of available CD16, CD16 nev-
ertheless appears to have an important role in signaling sur-
vival in the presence of this stimulus. Engagement of CD16
has been previously shown to prevent apoptosis of mono-
cytes in response to IL-10 (44). This mechanism operating
in vivo might lead to the death and clearance of CD16 
phagocytes that have performed their duties at sites of in-
flammation, but preserve the viability of phagocytes with
the capacity to migrate to lymph nodes as antigen-present-
ing DCs. On the other hand, CD16  monocyte-derived
cells may promote not only their own survival, but also the
survival and differentiation of CD16  cells in trans. Finally,
observations that FcRs critically participate in the genera-
tion of CTLs after antibody-mediated opsonization and
cross-presentation highlight the importance of FcR func-
tion in DCs during immune surveillance (45). The present
findings suggest that CD16  monocytes may serve as a ma-
jor pool of DC precursors with optimal capacity for FcR-
facilitated presentation in vivo.
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